Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  childhood acute promyelocytic leukemia (M3)
Stage/Subtype:  childhood acute promyelocytic leukemia (M3)
Country:  U.S.A.
Trial Type:  Treatment
Results 1-6 of 6 for your search:
Start Over
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Status: Active
Phase: Phase IV
Type: Treatment
Age: 3 months and over
Trial IDs: B1761026, NCI-2015-00700, NCT02312037
Clofarabine and Cytarabine or Standard Induction Therapy and Chemotherapy with or without Natural Killer Cell Transplant in Treating Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: AML08, NCI-2011-03659, NCT00703820
Tretinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: AAML1331, NCI-2014-02266, PAAML1331_A01PAMDREVW0, NCT02339740
Tretinoin and Arsenic Trioxide with or without Gemtuzumab Ozogamicin in Treating Patients with Previously Untreated Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 10 and over
Trial IDs: 2010-0981, NCI-2011-02767, NCT01409161
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: BECHEM, NCI-2013-01148, TEVA ISS, NCT01900509
Gemtuzumab Ozogamicin in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, or Chronic Myelogenous Leukemia
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 months and over
Trial IDs: CCCWFU# 99213, NCI-2013-00965, NCT01869803
Start Over